Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma.

ABSTRACT: Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.

SUBMITTER: Hsueh CT 

PROVIDER: S-EPMC4988316 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature